Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Phase 2

Recruiting

Conditions: Hepatopathy

Interventions: Drug: Placebo
Drug: Hetrombopag

First Posted Date: 2022-07-05

Last Posted Date: 2024-03-13

Lead Sponsor: Fudan University

Target Recruit Count: 96

Registration Number: NCT05442632

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Social Media-based Vaccine Confidence and Hesitancy Monitoring

Withdrawn

Conditions: Vaccination Refusal
Information Dissemination
Machine Learning
Internet-Based Intervention
Social Medium
Patient Acceptance of Health Care
Data Collection
Immunization Programs

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-05

Lead Sponsor: Fudan University

Registration Number: NCT05442762

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: chidamide
Drug: camrelizumab
Drug: capecitabine
Drug: carboplatin

First Posted Date: 2022-06-30

Last Posted Date: 2022-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT05438706

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Procedure: HAIC
Drug: Fruquintinib
Drug: Tislelizumab
Drug: Raltitrexed
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2022-06-28

Last Posted Date: 2024-01-17

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT05435313

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2022-06-22

Last Posted Date: 2022-06-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05426850

Locations: 🇨🇳
Fudan University Shanghai cancer center, Shanghai, Shanghai, China

Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Hypopharyngeal Cancer
Laryngeal Cancer

Interventions: Drug: Toripalimab

First Posted Date: 2022-06-15

Last Posted Date: 2022-06-15

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT05420597

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer

Not Applicable

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Combination Product: bevacizumab plus nab-paclitaxel and platinum

First Posted Date: 2022-06-07

Last Posted Date: 2022-06-07

Lead Sponsor: Fudan University

Target Recruit Count: 56

Registration Number: NCT05407155

Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery

Not Applicable

Completed

Conditions: Mammary Cancer
PONV

Interventions: Device: electric stimulation therapy

First Posted Date: 2022-06-07

Last Posted Date: 2023-09-26

Lead Sponsor: Fudan University

Target Recruit Count: 198

Registration Number: NCT05408676

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Phase 2

Recruiting

Conditions: Melanoma

Interventions: Drug: Tislelizumab
Drug: Lenvatinib
Drug: Cryoablation

First Posted Date: 2022-06-06

Last Posted Date: 2022-11-10

Lead Sponsor: Fudan University

Target Recruit Count: 25

Registration Number: NCT05406466

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Phase 2

Not yet recruiting

Conditions: Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Interventions: Drug: utidelone

First Posted Date: 2022-06-03

Last Posted Date: 2022-06-03

Lead Sponsor: Fudan University

Target Recruit Count: 61

Registration Number: NCT05403333

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy